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HYPERTROPHIC CARDIOMYOPATHY (HCM) is a primary cardiac disorder characterized by left ventricular (LV) hypertrophy (LVH), myocyte disarray, and cardiac fibrosis (21, 28) . The prevalence of HCM is estimated at 1 in 500 in the general population (29) . Mutations in 13 unique genes cause HCM and account for ϳ75% of familial HCM (44) . Most mutations occur in genes that encode proteins within the sarcomere, predominantly in cardiac myosin heavy chain and cardiac myosin-binding protein C (MyBP-C) (2) . In the early literature, correlations between HCM-causing mutations and phenotypes were recognized; favorable prognosis was observed in cardiac MyBP-C gene (MYBPC3) mutation carriers and poor prognosis for certain myosin heavy chain 7 (MYH7) mutations (5, 12, 22, 33) . However, data from meta-analysis revealed that precise genotype-phenotype relationships may not be determined due to the heterogeneous nature of the disease and the inconsistency of study design in each small cohort (27) . Interestingly, recent studies have demonstrated that clinical manifestations of HCM can be influenced by the dosage of mutations, as seen in subjects harboring compound mutations with severe clinical courses (4, 17, 18, 26, 36 -39, 42) .
The majority of HCM-related gene mutations are unique to a patient and their family members; different mutations are usually identified in unrelated HCM families (44) , although founder mutations that arose from a common ancestor have been reported in several previous HCM cohorts (3, 11, 14, 19, 25, 31, 32) . "Benign" mutations, such as MYBPC3, which exhibit a low mortality rate before reproductive age, can be transmitted to the next generation and can have founder effects (3) . Although phenotypes of founder mutation carriers can be diverse and range from asymptomatic to sudden cardiac death (3) , few data exist regarding the defining factors that modify the clinical courses of founder HCM-causing mutations.
In the present study, we identified a novel founder MYBPC3 mutation (Val762Asp) in 33 carriers from 19 HCM families. MYBPC3 Val762Asp was combined with another sarcomere gene mutation in five of these carriers, which together enabled us to assess genotype-phenotype correlations and to reveal whether the presence of compound mutations can contribute to the phenotypic diversity of carriers harboring a founder mutation in HCM. Furthermore, we performed in vivo zebrafish experiments to elucidate the functional consequences of MYBPC3 Val762Asp alone or MYBPC3 Val762Asp in combination with other mutations.
MATERIALS AND METHODS
Ethics statement. This research protocol was approved by the Bioethical Committee on Medical Researches of Kanazawa University School of Medicine (Kanazawa, Japan), and written informed consent was obtained from all subjects or their guardians.
Patients. We enrolled 488 unrelated HCM probands (111 women and 377 men) who were diagnosed at Kanazawa University Hospital and affiliated hospitals. HCM was diagnosed by the presence of a nondilated and hypertrophied LV on two-dimensional echocardiography (wall thickness Ն 13 mm) in the absence of other disease that could account for the hypertrophy (13) . The criteria were used in the diagnosis of HCM in probands as well as in the determination of phenotypes in families with the Val762Asp mutation. Other cardiomyopathies, such as dilated cardiomyopathy or LV noncompaction, were thus excluded from the studied population. Patients with coexisting HCM and hypertension were included in the study given the high prevalence of hypertension in previous HCM cohorts (7) .
Genetic analysis. DNA was isolated from peripheral white blood cells of all subjects using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI). Genomic DNA was amplified by PCR, and the oligonucleotide primers used to amplify exons of MYBPC3 were as previously reported (9) . Exon numbering was used according to Fig. 1 . Pedigrees of probands in which at least two carriers harboring only the cardiac myosin-binding protein C gene (MYBPC3) Val762Asp mutation are identified. A: partial sequence of exon 23 of MYBPC3. The c.2285TϾA mutation was identified, which leads to an aspartic acid substitution for valine in residue 762 in 19 of 488 probands (3.9%) with hypertrophic cardiomyopathy (HCM). B: haplotypes are listed (from top to bottom) for markers D11S905, D11S986, D11S4174, D11S1385, D11S1344, D11S4109, D11S1784, and D11S1350. Boxed haplotypes indicate affected haplotypes. Note that all mutation carriers harbored the same haplotype through D11S986 to D11S1350. MYBPC3 is located between D11S1344 and D11S4109. The genotypic and phenotypic status of subjects is indicated in the key.
National Center for Biotechnology Information conventions. The single-strand conformational polymorphism (SSCP) technique or high-resolution melting (HRM) analysis (LightScanner system, Idaho Technology, Salt Lake City, UT) was used for the detection of mutations.
Although PCR products from DNA of subjects harboring MYBPC3 Val762Asp did not show abnormal bands by SSCP analyses, they did by HRM analyses. We performed direct sequencing with ABI PRISM 310 when irregular bands or profiles were detected by SSCP or HRM analysis, respectively. The presence of the Val762Asp mutation, which abolishes a Tth111 restriction site, was confirmed by digestion of amplified genomic DNA with this restriction enzyme. The same method was then used to detect the Val762Asp mutation from family members of the probands and 400 chromosomes of 200 healthy volunteers. Linkage analysis around the MYBPC3 region on chromosome 11 was performed with eight microsatellite markers (D11S905, D11S986, D11S4174, D11S1385, D11S1344, D11S4109, D11S1784, and D11S1350). These markers are distributed in the 7.2-Mb region around MYBPC3. Other sarcomere genes, including MYH7, troponin T (TNNT2), troponin I (TNNI3), tropomyosin (TPM1), myosin regulatory light chain 2 (MYL2), myosin essential light chain 3 (MYL3), and ␣-cardiac actin (ACTN1), were also screened at their mutation hotspots.
Clinical evaluations. Standard M-mode and two-dimensional echocardiographic experiments were performed to identify and quantify morphological features of the LV. Electrocardiographic abnormalities were defined as follows: Q wave Ͼ 3 mm in depth and/or Ͼ0.04 s in duration in at least two leads except for aVR. LVH was assessed by Sokolow-Lyon voltage (RV5 ϩ SV1) Ն 3.8mV, ST segment depression of an upsloping type Ͼ 0.1 mV at 0.08 s after the J point, or those of horizontal or down-sloping type Ͼ 0.05 mV, and T-wave inversion Ͼ 0.1 mV except for aVR and V1 to V2 leads in the absence of conduction disturbance (24) .
Cardiac magnetic resonance (CMR) images were acquired using a 1.5-T Sigma MR unit (Echo speed CVi) with a cardiac coil (GE Medical Systems, Milwaukee, WI). Intravenous gadolinium diethylenetriaminepentaacetic acid was given (0.2 mmol/kg), and contrastenhanced images were acquired after 10 -15 min in 8 -10 identical short-axis planes and four-chamber view planes by inversion-recovery segmented gradient echo (41) . Inversion times were adjusted to the null normal myocardium (230 -350 ms) with voxel sizes of 2.0 ϫ 1.6 ϫ 8.0 mm. CMR data of carriers harboring MYBPC3 Val762Asp were retrospectively collected. The CMR database in our hospital indicated that 59 HCM patients were examined by CMR with late gadolinium enhancement (LGE-CMR). By comparing the CMR database with our HCM mutation database, we found that five carriers of Val762Asp had been examined by CMR.
Animals. All procedures were performed in conformity with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996). The study protocol was approved by the Bioethical Committee on Medical Research, School of Medicine, Kanazawa University. Zebrafish were raised and maintained at 28°C on a 14:10-h light-dark cycle. We used the hspGFF3A strain of zebrafish, which expresses green fluorescent protein in the heart (8) , to analyze the size and function of the cardiac ventricle. Zebrafish hearts at 72 hours postfertilization (hpf) were recorded by Leica digital camera (DFC 310 for color images and DFC 365 FX for fluorescence images) on a fluorescence stereomicroscope (Leica M205 A). Recorded movies were converted to M-mode images using the original software (a kind gift from Dr. Seiji Takashima and Dr. Hiroya Kondo) (40) . Ventricular dimensions and fractional shortening of the ventricle were then measured from the M-mode images (40) . The atrial area was quantified using ImageJ software (NIH).
In vitro transcription of mRNA. Wild-type (WT) MYBPC3 cDNA (NM_001044349) with two synonymous mutations at the morpholino oligonucleotide (MO) target sequence was subcloned into the ClaIEcoRI-digested pCS2ϩ plasmid expression vector. Ala745Asp or Arg815Gln, which correspond to human Val762Asp or Arg820Gln, respectively, was introduced into WT MYBPC3 cDNA. Capped mRNA was prepared with the mMessage mMachine SP6 kit (Life Technologies).
Morpholino design and injection. To knock down endogenous MYBPC3, MO targeted against the translational start site (MYBPC3 MO) was used. The sequence of MYBPC3 MO was 5=-CTCTG-GCATCCTGGTTGAGTGTCCC-3= (10), which corresponds to 16 bases upstream of the translation start site and 9 bases of the coding sequence of MYBPC3. MYBPC3 MO does not interfere with translation of coinjected MYBPC3 mRNA because the mRNA contains an 8-base mismatch in the 5=-untranslated region and a 2-base synonymous mismatch in the coding region (20) . The sequence of control MO was 5=-CTGTGCCATCCTCGTTCACTGTCCC-3=, which contains a 5-base mismatch. MOs were synthesized by Gene-Tools (Gene Tools, Philomath, OR).
MYBPC3 MO (2.5 ng) or control MO (2.5 ng) was injected in hspGFF3A strain zebrafish embryos at one cell stage to knock down endogenous MYBPC3. In the mRNA experiments, MYBPC3 MO (2.5 ng) was coinjected with WT MYBPC3 mRNA (200 pg), Ala745Asp mutant mRNA (WT MYBPC3 and Ala745Asp mutant, 100 pg each), or double mutant mRNA (Ala745Asp and Arg815Gln mutants, 100 pg each). At least 50 embryos were injected in each group. Quantitative measurements of cardiac size and function were performed in 18 zebrafish in each group. Embryos of zebrafish were raised at 28°C.
Statistical analysis. Statistical analyses were performed using IBM SPSS Statistics software (version 22) for Windows (IBM). Values are expressed as means Ϯ SD for clinical variables and means Ϯ SE for zebrafish data. Comparisons between continuous variables were made using Student's unpaired t-test. Categorical data were compared using the 2 -test or Fisher's exact test. For zebrafish experiments, comparisons of cardiac measurements in each mRNA injection group with the MYBPC3 MO group were made using one-way ANOVA with Bonferroni multiple-comparisons test for post hoc comparisons. Kaplan-Meier curves were compared using a nonparametric log rank test. P values of Ͻ0.05 were considered statistically significant. (Fig. 1A) . Clinical charac- teristics of the 19 probands are shown in Table 1 . This Val762Asp variant was not observed in any of the 400 chromosomes from 200 healthy individuals. The substitution of aspartic acid for valine at residue 762 was predicted to be possibly damaging on the structure and function of MyBP-C by PolyPhen-2 software (1). Relatives of these 19 subjects were further investigated; DNA samples from family members of 6 subjects of them were available, and Val762Asp was identified in a total of 33 carriers (16 men and 17 women) with a mean age of 53.1 yr old. Six of the thirty-three carriers (18%) were hypertensive. Clinical characteristics of the 33 carriers are shown in Table 1 .
RESULTS

Genetic results. From 488 probands, we identified a Val762Asp variant of MYBPC3 in 19 patients
Of these 33 carriers, 28 carriers had only Val762Asp and 5 carriers had Val762Asp and other sarcomere gene mutations (MYBPC3 IVS21ϩ1 gϾa, MYBPC3 Arg820Gln, or TNNT2 Phe110Ile), which had already been reported as disease causing (Table 2) (6, 22, 23, 45) . Figure 1B shows pedigrees in which MYBPC3 Val762Asp alone was identified in at least two carriers (Val762Asp carriers, n ϭ 12). Pedigrees in which MYBPC3 Val762Asp alone was identified only in the proband are shown in Fig. 2 (Val762Asp carriers, n ϭ 12). Figure 3 shows pedigrees in which compound heterozygotes or double mutation carriers who harbored Val762Asp and another mutation (n ϭ 5) were identified. Carriers harboring Val762Asp alone (n ϭ 4) or another mutation alone (n ϭ 7) are also shown in Fig. 3 . In the 28 carriers harboring only Val762Asp, 18 carriers showed overt HCM on echocardiography (closed circles or squares in Figs. 1B, 2, and 3) . None of the eight genetically unaffected subjects from families (open circles or squares in Figs. 1B and 3) showed HCM phenotypes in echocardiography. ECG abnormalities (any abnormal Q waves, high voltage in precordial leads, ST-T changes, or T wave inversion) were observed in 21 of the 28 carriers (75%) harboring only Val762Asp, whereas minor T wave inversion was observed in only one of the (Figs. 1B and 3) . Haplotype analyses in the five patients harboring MYBPC3 Val762Asp and another sarcomere gene mutation revealed that two of these patients were trans-compound heterozygotes with mutations of Val762Asp and IVS21ϩ1 gϾa (HCM-033 IV-2 and IV-9; Fig. 3 ). Two carriers harbored dual mutations in MYBPC3 Val762Asp and TNNT2 Phe110Ile (Fig. 3) . HCM-453 II-1 harbored MYBPC3 Val762Asp and MYBPC3 Arg820Gln. No further clinical information was obtained from the pedigree of HCM-453.
Val762Asp and its phenotypic expression. Clinical characteristics of the 28 carriers harboring only Val762Asp are shown in Table 3 . The mean maximal LV wall thickness was 15.2 Ϯ 5.2 mm. Negative T waves were the most frequent ECG abnormalities in the 28 carriers. Male carriers (n ϭ 15) showed greater maximal LV wall thickness, larger LV end-diastolic dimension, and left atrial dimension compared with female carriers (n ϭ 13).
Clinical manifestations of carriers harboring only MYBPC3 Val762Asp and those with other MYBPC3 mutations are shown in Table 4 . The extent of LV maximal wall thickness and LV ejection fraction were similar between the two groups. n, number of subjects. *Novel mutation. Note that massive fibrosis was observed in the compound heterozygote (B), whereas late gadolinium enhancement was not evident in the carrier with a single mutation (C).
Phenotypes of end-stage HCM, which is represented by a decreased ejection fraction of Ͻ50%, were rarely observed in both groups. Interestingly, the age of diagnosis for HCM was significantly older in carriers with only Val762Asp mutation (62.8 Ϯ 3.0 yr) than that in those horbaring other MYBPC3 mutations (50.1 Ϯ 2.6 yr, P Ͻ 0.05; Fig. 4A ). Evidently, 80% of only Val762Asp carriers lacked clinical evidence of HCM under the age of 30 yr. MYBPC3 Arg820Gln was a prevalent mutation in the "other MYBPC3 mutations" (Table 4 ) (22) . When electrocardiographic and echocardiographic parameters of carriers harboring only Val762Asp (n ϭ 28) were compared with those of carriers harboring only Arg820Gln (n ϭ 27), no difference was observed between the two groups (Table 5) .
Clinical phenotypes of compound heterozygotes and double mutation carriers. The clinical phenotypes of the three compound heterozygotes and two double mutation carriers harboring Val762Asp with other sarcomere gene mutations are shown in Table 2 . Substantial LVH at an early age was observed in two of three compound heterozygotes (66%) in MYBPC3 (Val762Asp and IVS21ϩ1 gϾa or Arg820Gln) and in none of the two carriers of double mutation (MYBPC3 Val762Asp and TNNT2 Phe110Ile). Furthermore, progression to end-stage HCM was observed in a compound heterozygote in MYBPC3 (Val762Asp and IVS21ϩ1 gϾa).
CMR was performed in two compound heterozygotes (HCM-033 IV-2 and HCM-033 IV-9) and three carriers harboring only Val762Asp (HCM-093 II-1, HCM-437, and HCM-579; Table 6 ). Both of the two compound heterozygotes showed diffuse LGE in the LV (LGE ϭ 19.8% in HCM-033 IV-2 and 23.8% in HCM-033 IV-9). On the other hand, of the three carriers harboring only Val762Asp, diffuse LGE was detected only in one carrier (LGE ϭ 11% in HCM-093 II-1). The other two isolated Val762Asp carriers showed only mild
LGE in the inferior segment or no LGE in the LV. Representative CMR images from a compound heterozygote with massive LGE and a carrier harboring only Val762Asp without LGE are shown in Fig. 4 , B and C, respectively.
Functional consequences of MYBPC3 Val762Asp alone or MYBPC3 Val762Asp in combination with other mutations.
We next tested whether injection of mRNA of MYBPC3 Ala745Asp (corresponding to human Val762Asp) alone or mRNA of MYBPC3 Ala745Asp in combination with another mutation (MYBPC3 Arg815Gln; corresponding to human Arg820Gln) had an effect on cardiac function and morphologies in zebrafish. MO targeted against the translational start site (MYBPC3 MO) was used to knock down endogenous zebrafish MYBPC3 (10). Ventricular dimension tended to increase in zebrafish injected with MYBPC3 MO compared with zebrafish injected with control MO (P ϭ 0.054; Fig. 5 ), which was consistent with the phenotype reported in a previous study (10) .
mRNA injection experiments revealed that ventricular dimension and heart rate at 72 hpf were similar between the MYBPC3 MO group (n ϭ 18) and the MYBPC3 MO with WT mRNA (200 pg) group (n ϭ 18) or the MYBPC3 MO with Ala745Asp mRNA and WT mRNA (100 pg each) group (n ϭ 18), whereas ventricular dimension and heart rate were significantly increased in the MYBPC3 MO with Ala745Asp mRNA and Arg815Gln mRNA (100 pg each) group (n ϭ 18) compared with the MYBPC3 MO group (ventricular dimension: 96.3 Ϯ 2.0 vs. 86.5 Ϯ 2.62, P ϭ 0.046; heart rate: 163 Ϯ 4 vs. 147 Ϯ 4 beats/min, P ϭ 0.023; Figs. 6 and 7) . Ventricular fractional shortening and atrial area were similar between these four groups (Figs. 6 and 7) . Furthermore, the survival rate of the MYBPC3 MO group at 72 hpf was 73% (n ϭ 56), which was rescued by coinjection of MYBPC mRNA; the survival rate was 94% (n ϭ 72) in the MYBPC3 MO with WT mRNA group, 93% (n ϭ 69) in the MYBPC3 MO with Ala745Asp mRNA and WT mRNA group, and 93% (n ϭ 58) in the MYBPC3 MO with Ala745Asp mRNA and Arg815Gln mRNA group (P Ͻ 0.0001 for the trend across all groups).
DISCUSSION
In the present study, the Val762Asp mutation in MYBPC3 was shown to be a prevalent disease-causing mutation identified in 3.9% of 488 unrelated Japanese HCM patients. Haplotype analyses revealed that this prevalence is due to a founder effect of the MYBPC3 Val762Asp mutation rather than a recurrent mutation of this residue. This genetic variant was found to be associated with late disease onset and mild ventricular hypertrophy (Tables 1 and 3 -5) , which is consistent with the mild phenotypes observed in founder mutation carriers described in previous studies (3, 11, 14, 19, 25, 31, 32) . Interestingly, when combined with another sarcomere gene mutation, early onset HCM and impairment of LV systolic function could be observed in some cases. The prevalence of the Val762Asp mutation could be explained by its association with mild clinical outcomes and few HCM-related deaths even among other MYBPC3 mutation carriers. Notably, the age at diagnosis was significantly higher in only Val762Asp carriers compared with those with compound mutations (Fig. 4A) , suggesting that this genomic defect might have less deleterious impacts on survival. Indeed, previously identified founder MYBPC3 mutations have been associated with mostly mild phenotypes (19) . The mild phenotypes were also observed in zebrafish with MYBPC3 Val762Asp mRNA injection; ventricular function and size were not significantly altered by injection of Val762Asp mRNA alone at 72 hpf (Figs. 6 and 7) .
In the present study, there were three compound heterozygotes and two double mutation carriers. Substantial LVH at an early age was observed in two of three compound heterozygotes (67%) in MYBPC3 (Val762Asp and IVS21ϩ1 gϾa or Arg820Gln) and in none of the two carriers of double mutation (MYBPC3 Val762Asp and TNNT2 Phe110Ile; Table 2 ). These findings indicate that compound heterozygotes in MYBPC3 may develop LVH earlier than those harboring double mutations (MYBPC3 Val762Asp and TNNT2 Phe110Ile). Because TNNT2 Phe110Ile has been reported to be associated with mild HCM phenotypes (6), one might speculate that combination of two benign mutations may not lead to early onset HCM. Alternatively, it can be postulated that two mutations in one sarcomere gene may deteriorate HCM phenotypes more severely than two mutations in two different sarcomere genes, which needs to be further explored.
It is worth noting that one compound heterozygote harboring been well documented in recent studies (17, 18, 26, 36, 38, 42) , progression to end-stage HCM has been reported only in a few studies (4, 15, 34) . Dosage effects of MYBPC3 mutations may lead to myocardial cell death and replacement fibrosis, which, in turn, deteriorates LV systolic function, because massive myocardial fibrosis was detected by LGE-CMR in a compound heterozygote in the present study. Moreover, recent studies (30, 43) demonstrated haploinsufficiency as the mechanism of HCM for both truncation and missense MYBPC3 mutations. Although MyBP-C protein levels in compound heterozygotes with MYBPC3 mutations have not yet been examined, we assume that not only WT but also mutated MyBP-C protein may be undetectable in the myocardium, thus contributing to the end-stage HCM phenotypes observed in compound heterozygote mutations. Further studies will be required to address MyBP-C protein expression in patients harboring multiple MYBPC3 mutations. Our data also indicated that compound mutations in MYBPC3 and/or double mutations in MYBPC3 and another sarcomeric gene may not necessarily result in severe phenotypes such as end-stage HCM (Table 2) . Indeed, HCM453-II-1 harboring Val762Asp and Arg820Gln in MYBPC3 did not show end-stage HCM, although we have previously reported that Arg820Gln is associated with end-stage HCM in the elderly (22) . Because HCM453-II-1 was young when clinically evaluated (11 yr old), the absence of the end-stage phenotype at this age is consistent with our previous data (22) . However, HCM453-II-1 showed substantial LVH at 11 yr of age, which was rarely observed in carriers harboring only Arg820Gln (22) . Together, we postulate that the presence of Val762Asp in this carrier harboring Arg820Gln might have exacerbated LVH but has not resulted in end-stage HCM at 11 yr of age. However, careful followup might be needed in this carrier because ventricular dimension was significantly increased in zebrafish with injection of both MYBPC3 Val762Asp and Arg820Gln mRNA (Fig. 7) .
This study has several limitations. First, we screened sarcomere gene mutations using SSCP or HRM analysis. Because the sensitivity of these analyses has been reported to be 70 -96% (16, 35) , some mutations may have been missed in the screening process. Furthermore, because not all of the coding exons of sarcomere genes were screened in the 488 probands with HCM, the exact prevalence of the compound or double mutations cannot be concluded. Second, there could be a patient selection bias for LGE-CMR due to retrospective data collection. Third, inhibition of MyBP-C protein expression by MO against the translation start site was not directly assessed due to the lack of available antibodies for zebrafish MyBP-C. Generation of genetically engineered zebrafish harboring tagged MYBPC3 will address this issue in the future. Nevertheless, we have two key results that might support evidence of MyBP-C protein knockdown. MO against the translation start site caused cardiac remodeling in zebrafish both in a previous study (10) and in the present study. Moreover, the survival rate of embryos injected with only MO against the translational start site was rescued when MO and MYBPC3 mRNA were coinjected, together supporting evidence of inhibition of MyBP-C protein expression by MO.
In conclusion, the founder Val762Asp mutation in MYBPC3 is a frequent cause of HCM in the Japanese population. This mutation alone is associated with a late onset of HCM. However, combination with another sarcomere gene mutations may Fig. 7 . Quantitative measurements of cardiac dimensions and function in zebrafish at 72 hpf. End-diastolic dimension of the ventricle (A) and heart rate (in beats/min; D) were significantly increased in the MO ϩ Ala745Asp ϩ Arg815Gln group compared with the MO group (ventricular dimension: 96.3 Ϯ 2.0 vs. 86.5 Ϯ 2.62, P ϭ 0.046; heart rate; 163 Ϯ 4 vs. 147 Ϯ 4 beats/min, P ϭ 0.023). Fractional shortening (B) and atrial area (C) were not different in the four groups (n ϭ 18 animals/ group). At least 50 embryos were injected in each group. Quantitative measurements of cardiac size and function were performed in 18 zebrafish/group. result in early disease onset or end-stage HCM in some cases. These results demonstrate that MYBPC3 Val762Asp may be associated with unfavorable HCM phenotypes in some cases when combined with another MyBP-C mutation. Future studies are needed to determine further genetic and environmental factors responsible for phenotypic variations of HCM.
